PIPELINE




Pipeline 1: SARS-CoV-2 Vaccines (Joint Development with MediciNova, Inc.)

BC-PIV with a SARS-CoV-2 mutated spike protein

The SARS-CoV-2 vaccine prototype has been developed to include the specific SARS-CoV-2 antigen protein in order to express maximum antigenicity.

Pipeline 2: Anti-Solid tumor agent (TAV:T cell-signaling anti-tumor virus )

BC-PIV with TNFRSF ligand OX40L/4-1BBL (TAV)

BC-PIV with TNFRSF ligand OX40L/4-1BBL (TAV) induces systemic anti-tumor immunity against the solid tumor, resulting in suppression of the tumor growth even at the remote site.

Pipeline3: RSV vaccine

BC-PIV/RSV F delivering prefusion conformation antigen F

BC-PIV/RSV F can deliver prefusion F through structure-based design of the recombinant vaccine, targeting both seronegative infants and elderly people.

Pipeline4: Ebola vaccine

BC-PIV/Ebola GP delivering GP protein of the Ebola virus.

BC-PIV/Ebola GP has safety profile with mutated GP which abolishes GP-mediated entry, but retains strong antigenic activity as an Ebola virus vaccine.

Vaccine Technology Background

BC-PIV is an abbreviation for BioComo-developed parainfluenza virus type 2 (hPIV2) vector system with a non-transmissible property by an F-envelope gene deletion in the genome, endowing a high safety profile. It is further characterized by the ability of delivering not only foreign genes but also foreign proteins with intact tertiary structure outside and/or inside the envelope (membrane), keeping strong antigenicity. BC-PIV can be administered through variety of routes such as intranasal, intramuscular, intradermal, subcutaneous, and intra-tumoral, as a therapeutic or a prophylactic vaccine vector.

Scope

BioComo focuses on infectious diseases by RSV, Ebora virus, and SARS-CoV-2, and also immune-oncology for solid tumors.

Infection

BC-PIV is vaccine carrier platform against infectious diseases, covering broad range of viral antigens from small peptide to full length protein, retaining intact structure as antigen. The RSV F with prefusion conformation has been suggested to induce neutralizing activity. The Ebola virus GP antigen with mutations for restriction of cell entry (non-propagation in recipients) has a safety profile, and reduces the adverse effects. BC-PIV can endow antigenicity through structure-based design of vaccine antigens and effectively elicits humoral immunity through intranasal and intramuscular injections. We have successfully developed BC-PIV with a modified RSV prefusion F, and with a modified Ebola GP in collaboration with Mie University (Japan). We will develop BC-PIV/SARS-CoV-2 spike protein in the near future.

Immuno-oncology

BC-PIV also holds strong capabilities to induce cellular immunity through intratumoral injection. We focus on immune-enhancers (BC-PIV/modified-OX40L or BC-PIV/modified-4-1BBL) against solid tumors which promote effector T cell function to induce tumor rejection in the host in the absence of adjuvants, similar to agonistic antibodies or an OX40 ligand with an Fc region in the presence of adjuvants for immune activation. Notably the in situ vaccination of BC-PIV/modified-OX40L or BC-PIV/modified-4-1BBL alone enhanced activities of effector T cells, promoted anti-tumor immunity, and eradicated the transplanted tumors at both injection and remote sites in animal models. We are developing a new treatment combining BC-PIV-based immune-enhancers with immune check point inhibitors.


Page Top